1715 38TH ST, BOULDER, CO
Annual Meeting Results: Election of Directors and Auditor Ratification
Announces Sale of Sevasemten for Up to $2.65 Billion, Strengthening Balance Sheet and Centering Focus on Cardiovascular Pipeline
Reports First Quarter 2026 Financial Results and Advances Clinical Programs in Muscular Dystrophy and Cardiovascular Indications
Annual Report to Security Holders
Reports Fourth Quarter and Full Year 2025 Financial Results with Strong Progress Across Muscular Dystrophy and Cardiovascular Programs
Appoints Commercial Biotech Executive Christopher Martin to its Board of Directors
Announces Appointment of Michael Nofi as Chief Financial Officer, and the Retirement of Current CFO, R. Michael Carruthers
Reports Third Quarter 2025 Financial Results and Recent Business Highlights
Q1
FY 2024
Q3
Q2
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
S-3ASR
Registration Statement for Additional Securities
Definitive Proxy Statement
Additional Proxy Materials
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities